Design of amphiphilic PCL-PEG-PCL block copolymers as vehicles of Ginkgolide B and their brain-targeting studies

References

• Zhou S, Deng X, Yang H. Biodegradable poly (-caprolactone)-poly (ethylene glycol) block copolymers: characterization and their use as drug carriers for a controlled delivery system. Biomaterials. 2003;24:3563–3570.10.1016/S0142-9612(03)00207-2
   PubMed Web of Science ®Google Scholar
• Gaucher G, Marchessault RH, Leroux J-C. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Controlled Release. 2010;143:2–12.10.1016/j.jconrel.2009.11.012
   PubMed Web of Science ®Google Scholar
• Ohya Y, Takeda S, Shibata Y, et al. Evaluation of polyanion-coated biodegradable polymeric micelles as drug delivery vehicles. J Controlled Release. 2011;155:104–110.10.1016/j.jconrel.2010.11.008
   PubMed Web of Science ®Google Scholar
• Fu S, Ni P, Wang B, et al. Injectable and thermo-sensitive PEG-PCL-PEG copolymer/collagen/n-HA hydrogel composite for guided bone regeneration. Biomaterials. 2012;33:4801–4809.
   PubMed Web of Science ®Google Scholar
• Endres T, Zheng M, Beck-Broichsitter M, et al. Lyophilised ready-to-use formulations of PEG-PCL-PEI nano-carriers for siRNA delivery. Int J Pharm. 2012;428:121–124.10.1016/j.ijpharm.2012.03.003
   PubMed Web of Science ®Google Scholar
• Gou M, Zheng L, Peng X, et al. Poly(epsilon-caprolactone)-poly(ethylene glycol)-poly(epsilon-caprolactone) (PCL-PEG-PCL) nanoparticles for honokiol delivery in vitro. Int J Pharm. 2009;375:170–176.10.1016/j.ijpharm.2009.04.007
   PubMed Web of Science ®Google Scholar
• Zheng M, Liu Y, Samsonova O, et al. Amphiphilic and biodegradable hy-PEI-g-PCL-b-PEG copolymers efficiently mediate transgene expression depending on their graft density. Int J Pharm. 2012;427:80–87.10.1016/j.ijpharm.2011.05.017
   PubMed Web of Science ®Google Scholar
• Zhang L, He Y, Yu M, et al. Paclitaxel-loaded polymeric nanoparticles based on PCL-PEG-PCL: preparation, in vitro and in vivo evaluation. J Controlled Release. 2011;152(Suppl 1):e114–6.10.1016/j.jconrel.2011.08.160
   PubMed Web of Science ®Google Scholar
• Dubey N, Varshney R, Shukla J, et al. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog. Drug Delivery. 2012;19:132–142.10.3109/10717544.2012.657718
   PubMed Web of Science ®Google Scholar
• Perret R, Skoulios A. Synthesis and characterization of polyoxyethylene/poly-epsilon-caprolactone copolymer sequence. Makromolekul Chem. 1972;156:143–156.10.1002/macp.1972.021560111
   Google Scholar
• Wang SJ, Chen HH. Ginkgolide B, a constituent of Ginkgo biloba, facilitates glutamate exocytosis from rat hippocampal nerve terminals. Eur J Pharmacol. 2005;514:141–149.10.1016/j.ejphar.2005.03.027
   PubMed Web of Science ®Google Scholar
• Chan WH. Ginkgolide B induces apoptosis and developmental injury in mouse embryonic stem cells and blastocysts. Hum Reprod. 2006;21:2985–2995.10.1093/humrep/del255
   PubMed Web of Science ®Google Scholar
• Grypioti AD, Kostopanagiotou G, Demopoulos CA, et al. Platelet activating factor (PAF) antagonism with Ginkgolide B protects the liver against acute injury. importance of controlling the receptor of PAF. Dig Dis Sci. 2008;53:1054–1062.10.1007/s10620-007-9982-2
   PubMed Web of Science ®Google Scholar
• Zhang S, Chen B, Wu W, et al. Ginkgolide B reduces inflammatory protein expression in oxidized low-density lipoprotein-stimulated human vascular endothelial cells. J Cardiovasc Pharmacol. 2011;57:721–727.10.1097/FJC.0b013e31821a50a8
   PubMed Web of Science ®Google Scholar
• Spinnewyn B, Blavet N, Clostre F, et al. Involvement of platelet-activating factor (PAF) in cerebral post-ischemic phase in Mongolian gerbils. Prostaglandins. 1987;34:337–349.10.1016/0090-6980(87)90079-7
   PubMed Web of Science ®Google Scholar
• Chu X, Ci X, He J, et al. A novel anti-inflammatory role for Ginkgolide B in asthma via inhibition of the ERK/MAPK signaling pathway. Molecules. 2011;16:7634–7648.10.3390/molecules16097634
   PubMed Web of Science ®Google Scholar
• Xia SH, Fang DC. Pharmacological action and mechanisms of Ginkgolide B. Chin Med J. 2007;120:922–928.
   PubMed Web of Science ®Google Scholar
• Yang ZZ, Li J, Li SX, et al. Effect of Ginkgolide B on striatal extracellular amino acids in middle cerebral artery occluded rats. J Ethnopharmacol. 2011;136:117–122.10.1016/j.jep.2011.04.027
   PubMed Web of Science ®Google Scholar
• Lv P, Fang W, Geng X, et al. Therapeutic neuroprotective effects of Ginkgolide B on cortex and basal ganglia in a rat model of transient focal ischemia. Eur J Pharm Sci. 2011;44:235–240.10.1016/j.ejps.2011.07.014
   PubMed Web of Science ®Google Scholar
• Zekri O, Boudeville P, Genay P, et al. Ionization constants of Ginkgolide B in aqueous solution. Anal Chem. 1996;68:2598–2604.10.1021/ac950939g
   PubMed Web of Science ®Google Scholar
• Suehiro M, Simpson NR, Underwood MD, et al. In vivo biodistribution of Ginkgolide B, a constituent of Ginkgo biloba, visualized by MicroPET. Planta Med. 2005;71:622–627.10.1055/s-2005-871267
   PubMed Web of Science ®Google Scholar
• Ferruti P, Tanzi MC, Rusconi L, et al. Succinic half-esters of poly (ethylene glycol) s and their benzotriazole and imidazole derivatives as oligomeric drug-binding matrices. Die Makromolekulare Chem. 1981;182:2183–2192.10.1002/macp.1981.021820807
   Web of Science ®Google Scholar
• Petrova T, Manolova N, Rashkov I, et al. Synthesis and characterization of poly (oxyethylene)–poly (caprolactone) multiblock copolymers. Polym Int. 1998;45:419–426.10.1002/(ISSN)1097-0126
   Web of Science ®Google Scholar
• Guan Y-m, You H-l, Wang J, et al. Determination of Ginkgolides in various Ginkgo leaves. Chin J Pharm Anal. 2001;21:107–109.
   Google Scholar
• Liu F, Schafer DP, McCullough LD. TTC, fluoro-Jade B and NeuN staining confirm evolving phases of infarction induced by middle cerebral artery occlusion. J Neurosci Methods. 2009;179:1–8.10.1016/j.jneumeth.2008.12.028
   PubMed Web of Science ®Google Scholar
• Longa EZ, Weinstein PR, Carlson S, et al. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989;20:84–91.10.1161/01.STR.20.1.84
   PubMed Web of Science ®Google Scholar
• Zhang RL, Chopp M, Zhang ZG, et al. A rat model of focal embolic cerebral ischemia. Brain Res. 1997;766:83–92.10.1016/S0006-8993(97)00580-5
   PubMed Web of Science ®Google Scholar
• Zhu Z, Xiong C, Zhang L, et al. Synthesis and characterization of poly (ϵ-caprolactone)-poly (ethylene glycol) block copolymer. J Polym Sci Part A Polym Chem. 1997;35:709–714.10.1002/(ISSN)1099-0518
   Web of Science ®Google Scholar
• Hu Y, Zhang L, Cao Y, et al. Degradation behavior of poly (ε-caprolactone)-b-poly (ethylene glycol)-b-poly (ε-caprolactone) micelles in aqueous solution. Biomacromolecules. 2004;5:1756–1762.10.1021/bm049845j
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhuo R. Synthesis and in vitro drug release behavior of amphiphilic triblock copolymer nanoparticles based on poly (ethylene glycol) and polycaprolactone. Biomaterials. 2005;26:6736–6742.10.1016/j.biomaterials.2005.03.045
   PubMed Web of Science ®Google Scholar
• Bezemer J, Radersma R, Grijpma D, et al. Zero-order release of lysozyme from poly (ethylene glycol)/poly (butylene terephthalate) matrices. J Controlled Release. 2000;64:179–192.10.1016/S0168-3659(99)00127-3
   PubMed Web of Science ®Google Scholar
• Mosqueira VCF, Legrand P, Morgat JL, et al. Biodistribution of long-circulating PEG-grafted nanocapsules in mice: effects of PEG chain length and density. Pharm Res. 2001;18:1411–1419.10.1023/A:1012248721523
   PubMed Web of Science ®Google Scholar
• Olivier JC, Fenart L, Chauvet R, et al. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharm Res. 1999;16:1836–1842.10.1023/A:1018947208597
   PubMed Web of Science ®Google Scholar
• Danafar H. MPEG–PCL copolymeric nanoparticles in drug delivery systems. Cogent Med. 2016;3:1142411.
   Google Scholar